Eli Lilly‘s (NYSE:LLY) Humalog Junior KwikPen insulin lispro injection is available in the U.S. by prescription for people with diabetes, the company said today.
The drug-device combination product is designed as a pre-filled, disposable half-unit insulin pen.
The Humalog Junior KwikPen won FDA approval in June this year and earlier last month, a European Medicines Agency committee recommended approval for the product.
“Learning how to inject insulin can be overwhelming, especially for newly diagnosed children and their caregivers. People often feel shock and anxiety, and may struggle with the reality of fitting diabetes into daily life,” Dr. Sherry Martin, VP of Lilly Diabetes’ global medical affairs, said in prepared remarks.
“We hope to help take away some of the worries about the injection process with Humalog Junior KwikPen. Because it is prefilled, there are fewer steps for people to learn, and the half-unit increments make dosing more precise.”
The injection pen is for people with diabetes who want the precision of half-unit dosing, the company said, including those with insulin sensitivity.
